Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Last trade$34.56
Day change-$0.84 (-2.37%)
Day range$34.24 – $36.20
Volume401,888
Market cap$2.66B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.66B
Price / earnings
—
Price / book
4.74×
Price / sales
13.25×
EV / sales
13.43×
EV / EBITDA
-19.81×
Profitability
Earnings per share
-$1.57
Return on assets
-15.3%
Return on equity
-21.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.17×
Current ratio
6.54×
Quick ratio
6.54×
Cash ratio
0.78×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$176.45M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XNCR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$116.52M
$51.22M
$4.52M
$28.24M
$21M
$43.61M
$32.73M
$52.79M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$116.52M
$51.22M
$4.52M
$28.24M
$21M
$43.61M
$32.73M
$52.79M
Selling, general and administrative
$9.36M
$16.38M
$17.71M
$17.04M
$14.15M
$15.12M
$17.34M
$14.92M
Research and development
$84.3M
$71.91M
$64.67M
$64.82M
$54.37M
$61.67M
$58.58M
$51.06M
Total operating expenses
$93.66M
$89.09M
$82.38M
$81.87M
$70.08M
$78.64M
$75.92M
$65.97M
Operating income
$22.86M
-$37.87M
-$77.86M
-$53.63M
-$49.08M
-$35.03M
-$43.18M
-$13.18M
Interest expense
-$4.11M
-$7.35M
-$4.7M
-$7.35M
-$7.67M
-$8.24M
-$8.67M
-$8.66M
Income before taxes
$39.26M
-$21.92M
-$128.64M
-$4.27M
-$6.03M
-$31.08M
-$48.27M
-$44.58M
Income taxes
-$175K
-$190K
$280K
$2.39M
$0
-$250K
$367K
$1.62M
Net income
$39.44M
-$21.73M
-$128.92M
-$6.65M
-$6.03M
-$30.83M
-$48.63M
-$46.2M
Net income attributable to common shareholders
$39.44M
-$21.73M
-$128.92M
-$6.65M
-$6.03M
-$30.83M
-$48.42M
-$45.55M
EBITDA
$25.1M
-$34.63M
-$75.3M
-$51.05M
-$44.93M
-$30.52M
-$40.49M
-$10.18M
Basic earnings per share
$0.52
-$0.29
-$1.71
-$0.09
-$0.08
-$0.41
-$0.66
-$0.62
Diluted earnings per share
$0.50
-$0.29
-$1.71
-$0.09
-$0.08
-$0.41
-$0.66
-$0.62
Recent news
Company coverage with links to the original publishers.
Xencor (XNCR) reported quarterly earnings of $0.5 per share, significantly beating the consensus estimate of a loss of $0.35 per share, with revenues of $116.52 million surpassing estimates by 76.89%. Despite the strong earnings surprise of +242.86%, the stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The company has outperformed the S&P 500 by 100.1% year-to-date, but analysts expect underperformance in the near term.
A comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations and bispecific antibodies.
The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expansion initiatives across North America, Europe, and Asia-Pacific regions.
Xencor reported strong Q2 2025 financial performance with revenue of $43.6 million, beating estimates by 93%. The company advanced several clinical programs in oncology and autoimmune disorders and received a significant milestone payment from Incyte.
The global Ultomiris drug market is expected to grow from USD 4.16 Billion in 2024 to USD 64.12 Billion by 2034, with a robust 31.52% CAGR, driven by increasing demand for long-acting treatments for rare disorders like PNH and gMG.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.